Rinvoq (upadacitinib) is a once-daily JAK inhibitor tablet prescribed for ulcerative colitis and Crohn's disease. If you stop it, the drug leaves your blood within a few days, and in the studies that tested this, ulcerative colitis or Crohn's disease control was lost far more often than in people who kept taking it. In the ulcerative colitis maintenance trial, 12% of people switched to placebo were in remission a year later, against 42% to 52% of those who stayed on upadacitinib (Danese 2022). This guide explains what that does and does not tell you, what is known about missed doses and restarting, and what to write down so your prescriber has real dates and numbers to work with.
If you are here because you missed a few doses, a pharmacy or insurance gap interrupted your supply, the acne or the lab results are wearing you down, or you simply wonder what would happen, that is a normal thing to ask. Nothing on this page is advice to stop, pause, skip, restart, taper or change the dose of any medicine. Every one of those decisions belongs to the clinician who prescribes it, and the safest next step after any interruption is a call to their office. What this page can do is lay out the evidence in plain English so that call is shorter and better informed.
What happens if you stop Rinvoq?
In the main trial data, people who stopped upadacitinib lost control of ulcerative colitis or Crohn's disease far more often than people who continued. After responding to 8 weeks of induction, those re-randomized to placebo had 12% clinical remission at week 52, versus 42% and 52% on the two maintenance doses (Danese 2022).
That is the honest headline, and it matches the blunt tone of the most upvoted replies in r/UlcerativeColitis, where a recent thread asking what happens if you stop Rinvoq draws mostly one message: the most likely outcome is that symptoms come back, and many people who take it would accept side effects over an active flare (r/UlcerativeColitis). The same thread also contains the other thing worth taking from the community: several people say they told their doctor they were struggling with side effects and a different treatment was arranged, rather than quitting alone. That is not a loophole. It is the pathway the label and the guidelines assume.
Two cautions keep the numbers honest. First, the trial placebo group is not the same as a person who stops a drug that was working. Everyone in that group had responded to induction, but not everyone was in remission, so some of the 88% not in remission at one year never got there. Second, trials of this design report where people are at a fixed time point, not when they relapsed. If you want timing, you need a different kind of study, and we cover the nearest one below.
How long does Rinvoq stay in your system?
Rinvoq clears quickly. The US prescribing information reports a mean terminal elimination half-life of 8 to 14 hours (prescribing information). Using the common rule of thumb that most of a drug is eliminated after about five half-lives, that works out to roughly two to three days.
That arithmetic is ours, not a figure from a study, so treat it as an estimate. It also answers a different question from the one most people are really asking. How long the drug is detectable in blood is a pharmacology question. How long your bowel stays calm is a disease question, and the two do not line up. The label notes that body weight, sex and race had no clinically meaningful effect on exposure in adults, but it says nothing about how long inflammation stays suppressed after the last dose. For that we need trials in which people stopped, and the closest ones are the placebo-withdrawal arms.
This short half-life has one more practical consequence that is easy to miss. Because the drug is cleared in days, interruptions of any length are physiologically real, including the accidental ones. There is no long tail of drug in the body that quietly covers a missed week, which is one reason doctors ask you to tell them about gaps instead of assuming they do not matter.
What do the ulcerative colitis trials show when people stopped upadacitinib?
The U-ACHIEVE maintenance study is the cleanest look at what happens when upadacitinib is withdrawn in ulcerative colitis. Responders to 8 weeks of 45 mg induction were randomly assigned to continue the drug at one of two maintenance doses or to switch to placebo for 52 weeks. Remission was 12% on placebo against 42% and 52% on the two doses (Danese 2022).
The final analysis of the whole maintenance population, which included more people, came out the same way: 10.8% on placebo versus 40.4% and 53.6% on the two doses (Vermeire 2023). The label reports the same maintenance trial under the name UC-3 and breaks it down further.
| Week 52 outcome (UC maintenance trial) | Placebo | Lower dose | Higher dose |
|---|---|---|---|
| Clinical remission | 12% | 42% | 52% |
| Corticosteroid-free clinical remission | 22% | 57% | 68% |
| Endoscopic improvement | 14% | 49% | 62% |
| Histologic endoscopic mucosal improvement | 12% | 35% | 50% |
Source: prescribing information, Table 26. Percentages are of people in each group who had responded to induction.
The adverse-event data tell a quiet but important story. The most commonly reported adverse event in the placebo group was worsening of ulcerative colitis itself: 30% on placebo, versus 13% on the lower dose and 7% on the higher dose (Danese 2022). Serious adverse events were also more common on placebo (13%) than on either dose (7% and 6%), and adverse events that led people to stop the study were 11% on placebo versus 4% and 6%. In other words, in this trial the placebo arm was not the safe, side-effect-free option. The disease did the damage.
For the people who stayed on the drug, the long-term extension offers some reassurance about durability. Among those who entered the extension in clinical remission, 78% to 84% were still in remission at week 96, depending on dose (Panaccione 2025). This is as-observed data from people who stayed in the study, so it flatters the result, but it shows that when the drug works, many people keep the benefit for years.
What do the Crohn's disease trials show?
Crohn's disease shows the same direction. In U-ENDURE, people who responded to 12 weeks of induction were re-randomized to a lower maintenance dose, a higher dose or placebo. Clinical remission at week 52 was 15.1% on placebo versus 37.3% and 47.6% (Loftus 2023).
Endoscopic response, a measure of what a scope shows, was 7.3% on placebo versus 27.6% and 40.1% in the same analysis. The final results for all 673 patients were consistent: clinical remission of 15.2% on placebo versus 36.2% and 51.5%, and endoscopic response of 7.2% versus 27.3% and 40.7% (Panaccione 2026). The prescribing information gives slightly different rounding for the same trial (14%, 42% and 55% for clinical remission) because it reports the primary analysis population.
As with ulcerative colitis, the trials were designed to show that the drug works, not to model what a stopped patient experiences. The practical reading is the same in both conditions: in these studies, many people who were switched off upadacitinib lost ground compared with those who stayed on it. If you have Crohn's and your question is about stopping a different drug class, our guide to stopping Crohn's medication in remission covers the anti-TNF withdrawal studies, which do not transfer to a JAK inhibitor.
How quickly do symptoms come back after stopping a JAK inhibitor?
For upadacitinib specifically, we could not find a published median time to relapse after stopping. The nearest data come from tofacitinib, a related Janus kinase inhibitor. In OCTAVE Sustain, people switched to placebo had a median time to treatment failure of 169 days if they had been in remission after induction, and 123 days if they had responded without reaching remission (Panes 2021).
Note what that is and is not. It is a different drug, taken twice a day, studied in a trial where "treatment failure" had a protocol definition. It is not a prediction for you. But it does suggest something that matches how people describe it: for many, control does not collapse the week after the last dose. It erodes over weeks to months, and there is wide variation. In the same OCTAVE Sustain trial, 11.1% of people on placebo were in remission at week 52, versus 34.3% and 40.6% on the two tofacitinib doses (Sandborn 2017), a pattern very close to what upadacitinib showed.
The lived-experience version fits. In a separate r/UlcerativeColitis thread about forgetting doses, one commenter describes a long gap caused by insurance paperwork and says symptoms crept back gradually rather than arriving all at once (r/UlcerativeColitis). One person's account is not evidence, and others in the thread were more relaxed about a single missed day. But it is a useful reminder that a gradual return is exactly what a daily symptom log can catch before it becomes a flare. If your gap was caused by cost or insurance, our guide to affording ulcerative colitis medication covers who to call.
Will Rinvoq work again if you restart it?
We found no published study of upadacitinib restarted after a planned or accidental gap in ulcerative colitis or Crohn's disease. For the related drug tofacitinib, re-treatment worked in many people: after those who lost control on placebo were re-treated, 74.0% had a clinical response at month 2 and 39.0% were in remission (Panes 2021).
That tofacitinib paper is the best available picture of "recapture," the term researchers use for regaining response after treatment is interrupted. It reported that efficacy was recaptured regardless of whether people had previously failed an anti-TNF biologic, and the safety profile on re-treatment looked consistent with the main trials. But it is a different drug, a trial population and a protocol-led restart. It does not mean restarting upadacitinib is guaranteed to work, and it does not mean a gap is harmless. A flare in the meantime still costs you weeks, and it may mean steroids or a hospital stay first.
There is one real-world upadacitinib number worth knowing, with a clear label on what it is. In a Spanish multicenter study of 100 people with Crohn's or ulcerative colitis, most of whom had tried several advanced therapies, dose escalation recaptured remission in 60% of those who had relapsed while on the drug (García 2025). That is relapse during treatment and a prescriber-directed dose increase, not stopping and restarting. It shows that a loss of control on upadacitinib is sometimes recoverable by changes your doctor can make, which is another reason to report it early. Whether to restart, and how, is a decision for your prescriber and depends on why you stopped.
What if you only miss a dose or a few days?
We found no colitis or Crohn's study that tested single missed doses, so there is no trial number for a day or two. What exists is label wording, and it differs by country. The US prescribing information we read contains no missed-dose rule and tells you to take the medicine exactly as your healthcare provider says (prescribing information).
New Zealand's consumer medicine information is more specific: if you miss a dose, take it as soon as you remember as long as it is at least 10 hours before your next dose; if you forget for an entire day, skip the missed dose and take a single dose the next day; never take a double dose to catch up (Medsafe). Other countries have their own leaflets. We are quoting that one to show the range, not to give you a rule, because the instruction that applies to you is the one your prescriber or pharmacist confirms for your product and your situation.
Community advice on single missed days is relaxed, and mostly sensible in tone: set an alarm, do not double up, and call the clinic if it keeps happening. Some commenters also mention that clinicians have told them to hold the drug for a few days during an illness or a course of antibiotics. That is worth understanding, because it is the legitimate way interruptions happen. The label itself says treatment is to be interrupted if you develop a serious infection until it is controlled, and may need to be interrupted for abnormal blood counts or suspected drug-induced liver injury (prescribing information). Those decisions are made by your team using your results. Do not self-diagnose your way into one.
Whatever the cause, write it down. Note the date, how many doses were missed, and why: forgot, ran out, side effect, illness, procedure, or a clinician told you to hold. A clean record of the gap is more useful to your prescriber than a vague memory of "a week or so."
Do you need to taper off Rinvoq?
The US prescribing information gives no tapering schedule for ulcerative colitis or Crohn's disease. It does give maintenance doses of 15 mg once daily, with 30 mg considered for people with refractory, severe or extensive disease, and it tells prescribers to use the lowest effective dose needed to maintain response (prescribing information).
So the label contains a "lowest effective dose" principle but no step-down protocol, and the trials switched people directly from drug to placebo rather than testing a taper. We are not aware of a published trial of tapering upadacitinib in IBD. This matters because the phrase "tapering off" appears all over search results as if it were a standard step. For this drug in these conditions, it is not a documented one. Whether a lower dose is appropriate for you, and what to monitor if so, is a conversation to have with your gastroenterologist, who can see your scores, your calprotectin and your scope results.
Guidelines do not fill the gap. The American Gastroenterological Association's living guideline recommends upadacitinib as an option for moderate-to-severe ulcerative colitis, and its published withdrawal statements concern TNF antagonists and immunomodulators, not JAK inhibitors (Singh 2024). There is no guideline rule of the form "after a set period in remission, stop upadacitinib."
Does stopping Rinvoq cause withdrawal symptoms?
The US prescribing information describes no withdrawal syndrome for upadacitinib, and we found no published study documenting one in colitis or Crohn's. Some people in patient forums say they noticed itching or other changes after stopping. Those reports are anecdotes, and we cannot tell you they are or are not drug related.
The distinction worth holding onto is between withdrawal, where a body reacts to the absence of a drug, and relapse, where the underlying disease returns when it is no longer suppressed. The evidence above is about relapse, and it is substantial. If you stop or miss doses and notice something new, such as skin changes, itching, fatigue, joint pain or mood changes, do not try to work out the cause yourself. Write it down with the date and tell your prescriber. If it turns out to be nothing, you have lost two minutes. If it is the first sign of something else, you have a timeline.
Why do people think about stopping, and what does the label warn about?
People most often raise stopping because of side effects, lab results, cost, infection worries or simply wanting a break. The label's boxed warning covers serious infections, mortality, malignancy, major adverse cardiovascular events and thrombosis (prescribing information). Those are reasons to have the conversation, not reasons to decide alone.
The side effects people raise most in the Reddit thread are acne, constipation and fatigue or lab changes. In ulcerative colitis induction trials, acne was reported by 6% on the 45 mg induction dose versus 1% on placebo, and upper respiratory infections by 9% versus 7% (prescribing information). In the maintenance study, herpes zoster occurred at 6.0 and 7.3 events per 100 patient-years on the two doses and none on placebo, and hepatic disorders, creatine phosphokinase elevation and neutropenia were more frequent on upadacitinib than placebo (Vermeire 2023). Adjudicated major cardiovascular and venous thromboembolic events were infrequent in the trials, and all those on upadacitinib occurred in people with known risk factors.
Two label details are specific to bowel disease. First, medication residue has been reported in stool or ostomy output, mostly in people with shortened gut transit times; the label says to contact your provider if it is seen repeatedly. Second, the label lists blood counts and liver tests as things to monitor, which is why blood tests on a biologic or similar drug are routine. If your reason for wanting to stop is a side effect, tell your team what it is and when it started. They can check it, treat it, or discuss other options, including the choices in our guides on what to do when a biologic stops working and whether biologics are worth it for ulcerative colitis.
What should you log if you missed doses or stopped?
Log what a prescriber can act on: the dates of any gap, daily stool count, blood, urgency, night-time trips and pain, plus new side effects and the dates of any labs or calprotectin. A simple stool-frequency and bleeding record is enough to follow ulcerative colitis. In a trial analysis, the stool-frequency and bleeding items alone tracked patient-perceived response as well as the full Mayo score (Lewis 2008).
Symptom logs matter more than usual during an interruption because things can change quickly. In the induction trials, people on upadacitinib showed significant symptom improvements in stool frequency, bleeding, pain and urgency within the first one to three days, and about half reached a fecal calprotectin drop of more than 50% by week 2 (Loftus 2023). Symptoms can move on the scale of days, so a daily record catches both a slow slide and a quick one.
A useful gap log has these columns:
- Dose record. Date and time of each dose taken, each dose missed, and the reason.
- Bowel pattern. Number of stools, any blood, urgency, accidents, and trips that wake you at night, as in how to track symptoms during a flare.
- Pain and fatigue. A simple 0 to 10 score.
- Possible side effects. Skin changes, new infections, cold sores or shingles-like rash, fever.
- Test dates. Last calprotectin, blood tests and scope, so you can see how far back your last objective check was.
- A weekly score. Our PRO-2 guide shows how stool frequency and bleeding become a number.
Why not rely on symptoms alone? Because they can mislead in both directions. The American Gastroenterological Association suggests a biomarker-based strategy alongside symptoms, with fecal calprotectin below 150 µg/g used to rule out active inflammation in people in symptomatic remission (Singh 2023), and a pooled analysis found calprotectin predicted relapse in quiet IBD with 78% sensitivity and 73% specificity (Mao 2012). Those tests are ordered by your team. What you can contribute is the timeline.
Clairop logs meals, symptoms and stool in seconds, then looks for the foods your gut reacts to, including reactions that land days later.
A symptom tracker can keep the log in one place. Clairop records stools with blood, urgency and night-time detail, logs medication taken, calculates PRO-2 for ulcerative colitis from answers you have already given, and turns it into a one-page report for your appointment; see how it works. It is iPhone only, relies on patient-entered data and is not a medical device, so it cannot judge inflammation or tell you whether to take a dose. It records what happened so the person who can decide has the facts. You can compare options in our best apps for ulcerative colitis list.
What should you ask your prescriber?
Ask for a plan that names the next step in advance. Bring your gap log and use questions like these, adapted from our questions to ask your gastroenterologist about colitis and how to prepare for a GI appointment:
- I missed doses on these dates. Does that change anything, and who should I call if it happens again?
- If I have to be off it for an infection, surgery or procedure, who decides when it is resumed and what do I track?
- Is my current maintenance dose the lowest effective one for me, and what would we check before ever changing it?
- If side effects are the problem (acne, lab changes, infections), what can we do about them and what are the alternatives?
- Which tests should we do now: calprotectin, blood counts, liver tests, a scope?
- If my symptoms come back, what is the threshold for calling you the same day?
- If cost or insurance interrupts my supply, who in the clinic can help me avoid a gap?
- If we decide to change treatment, what is the plan so I am never left untreated in between?
When should you see a doctor promptly?
Call your IBD team the same day if you have stopped or missed doses and notice blood in your stool, a rising stool count, new or worse abdominal pain, fever, vomiting, unexplained weight loss, waking at night to pass stools, or signs of infection such as a painful rash, cough or burning urine. Our guide to how to tell whether your ulcerative colitis is flaring lists what counts.
Go to emergency care for heavy bleeding, severe or constant abdominal pain, a swollen or rigid abdomen, a fast pulse with fever, signs of dehydration, or chest pain, leg swelling or sudden breathlessness (the label's boxed warning includes thrombosis and cardiovascular events). Our guide on when to go to the hospital for a UC flare covers the numbers hospitals use. Do not wait for a scheduled appointment with these symptoms, and do not restart or adjust medication yourself in the meantime unless your clinician tells you to.
Common myths about stopping Rinvoq
- "If I feel fine for a week or two, I do not need it." Control can fade gradually over weeks to months, so feeling fine early does not show the drug is not needed. In the tofacitinib trial, medians were 4 to 6 months (Panes 2021).
- "Placebo is the safe option." In the UC trial, worsening colitis was the most common adverse event on placebo (30%), and serious adverse events were more common there than on either dose (Danese 2022).
- "It has a long half-life so a missed week is covered." The label half-life is 8 to 14 hours, so there is no long cover (prescribing information).
- "I can always restart and get back to where I was." Often plausible from the tofacitinib data, but it is a different drug, and a flare comes first (Panes 2021).
- "Tapering is the standard way to stop." The label gives no taper schedule, and no taper trial was found.
- "Itching after stopping is proof of withdrawal." It is a forum anecdote. No published evidence either way, so report it.
- "Calprotectin tells me if I can stop." It helps your team judge inflammation and relapse risk, but it is not a stopping rule (Mao 2012).
What the research cannot tell you
The trials were built to prove the drug works, not to describe real-world interruptions. The placebo arms mix people who were in remission with people who had only responded, and they report one time point, not a relapse date. We found no upadacitinib study of restarting after a gap, no taper trial and no single-missed-dose study. Guidelines do not name JAK inhibitors in their withdrawal statements.
What this means in practice is that anyone who gives you a confident number for "how fast it will come back" or "how well it will work again" is going beyond the evidence. The honest range is wide: some people feel fine for weeks, some deteriorate sooner, and nobody can predict which you will be. That uncertainty is exactly why the decision is made with someone who can see your results, and why a dated record of what you actually experienced is worth more than a forecast.
If you want broader context on medicine withdrawal in colitis, including 5-ASA, thiopurines and biologics, read can you live without medication with ulcerative colitis. If you are running out of options after other drugs have stopped working, what to do when all biologics fail in Crohn's and how often people switch biologics for Crohn's describe what the next steps can look like.
The short version
Stopping Rinvoq is followed, in the trials, by loss of remission in most people, with timing that is gradual rather than sudden and highly variable. The drug is cleared in days, restart data come from a sister drug, missed-dose rules differ by country, and no taper schedule exists in the label. None of that is a reason to act alone, and all of it is a reason to call your prescriber and bring a clear, dated log.




